Review Open Access Logo

Anemia in children: A review

Siti Nur Nabeela A’ifah Mohammad 1
Salfarina Iberahim 1, 2
Wan Suriana Wan Ab Rahman 2, 3
Mohd Nazri Hassan 1, 2
Hisham Atan Edinur 4
Maryam Azlan 4
Zefarina Zulkafli 1, 2, *
  1. School of Medical Sciences, School of Dental Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
  2. Hospital Pakar Universiti Sains Malaysia, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
  3. School of Dental Sciences, School of Dental Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
  4. School of Health Sciences, School of Dental Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
Correspondence to: Zefarina Zulkafli, School of Medical Sciences, School of Dental Sciences, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia; Hospital Pakar Universiti Sains Malaysia, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia. Email: zefarinazulkafli@gmail.com.
Volume & Issue: Vol. 12 No. 10 (2025) | Page No.: 7837-7845 | DOI: 10.15419/wnsrrk33
Published: 2025-10-31

Online metrics


Statistics from the website

  • HTML Views: 5
  • PDF Views: 0
  • XML Views: 0

Statistics from Dimensions

This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. 

Abstract

Anemia represents a significant global health challenge, particularly among children. It arises from multiple causes. The impact of anemia is substantial, leading to fatigue and weakness, which can restrict physical activity. In children, it can also impair cognitive development, affecting learning ability and concentration. This underscores its profound influence on overall quality of life and developmental outcomes. Effective control of anemia demands a comprehensive approach. Early detection and timely intervention are critical to mitigating the long-term consequences of anemia on individuals and communities. Reducing anemia, especially in children, is cost-effective and yields substantial health benefits. Therefore, to achieve prevention, it is important to raise awareness in the community about anemia and its complications, because mild or moderate anemia, if unrecognized and untreated, can progress to severe and life-threatening stages. Accordingly, this review offers a comprehensive overview of anemia, encompassing inherited and acquired causes. It includes prevalence rates, regional studies, and detailed tables. Finally, the integration of scientific references and study findings confers validity, rendering it a supported and informative review.

Introduction

Anemia remains a major public health problem. Approximately 1.62 billion individuals worldwide are affected, with a particularly high prevalence among children 1. According to the World Health Organization (WHO), anemia in adults is defined as a hemoglobin (Hb) concentration of <12 g/dL in women and <13 g/dL in men. In children, the WHO Hb cut-off values vary by age, as summarized in Table 1. The prevalence of anemia in children in Colombo-PR is 34.7 % 2. In Brazil, the prevalence of mild anemia in children (25 %) is higher than that of moderate anemia (9.9 %) 3. The etiology of pediatric anemia is heterogeneous; most affected children are asymptomatic, and the condition is often detected during routine health screening.

Table 1

Hemoglobin level based on severity of anemia in children

Anemia (g/dL)
Age of childrenNormalMildModerateSevere
5 years of age and below11.010.0-10.97.0-9.90< 7
5-11 years11.511.0-11.48.0-10.9< 8.0
12-14 years12.011.0-11.98.0-10.9< 8.0
15 years of age and above>12.010.0-10.97.0-9.9> 7.0

Methods

This review was conducted to provide a comprehensive overview of anemia in children, focusing on its prevalence, causes, diagnosis, and management. A structured literature search was performed across the following electronic databases: PubMed, Scopus, and Google Scholar, covering the period from 1993 to 2023. The search terms used included combinations of the following keywords: "anemia", "pediatric anemia", "children", "iron deficiency anemia", "nutritional anemia", "hemoglobin", and "pediatric hematology", using Boolean operators (AND, OR) to refine the search.

Inclusion criteria were peer-reviewed original research articles, reviews, and clinical guidelines written in English that addressed the epidemiology, etiology, diagnosis, treatment, or prevention of anemia. Exclusion criteria included non-English articles and studies focusing exclusively on adults or on other hematologic disorders not primarily related to anemia. The findings from the selected literature were synthesized thematically, focusing on major areas such as prevalence, etiology, clinical presentation, treatment, and preventive strategies.

Inherited anemia

Hereditary disorders of red blood cells (RBCs) arise from mutations or deletions in specific genes and can result in accelerated RBC destruction and anemia due to decreased hemoglobin (Hb) levels. These inherited RBC disorders include defects in hemoglobin (hemoglobinopathies), the RBC membrane (membranopathies), and RBC enzymes (enzymopathies) 4.

Hemoglobinopathy

Hemoglobinopathies constitute one of the most prevalent genetic disorders among children worldwide. They are broadly classified into two groups: thalassemias and structural hemoglobin (Hb) variants (abnormal hemoglobins) 5.

Thalassemias are subdivided into β-thalassemia and α-thalassemia, whereas common Hb variants include HbS, HbE, and HbC 6,7. Thalassemia affects both sexes and is particularly prevalent in the Mediterranean basin, Africa, the Middle East, the Indian sub-continent, and South-East Asia. Approximately 80 million individuals are carriers and 300 000–400 000 children are born annually with severe phenotypes. Recent investigations have concentrated on the prevalence, molecular genetics, and clinical consequences of α- and β-thalassemia 8-9.

For example, neonatal screening of 1438 infants in Hainan Province, China (2020–2021), identified 1024 thalassemia carriers, most of whom had α-thalassemia; comparable prevalence figures have been reported from Thailand and Malaysia 10,11,12,13,14. In South-East Asia, HbE/β-thalassemia represents a frequent and clinically important phenotype that often necessitates regular transfusion therapy. Owing to increasing migration and inter-marriage, its prevalence is expanding worldwide 15,16,17. Public-health interventions—including prenatal and premarital screening, population education, and genetic counselling—have demonstrated efficacy in lowering disease burden 17.

Structural Hb variants arise from mutations, deletions, substitutions, stop-codon read-through (antitermination), or aberrant post-translational modifications of the globin chain 18. As for thalassemia, the prevalence of Hb variants is augmented by consanguineous marriage and population migration. The most prevalent variants are HbE, HbC, and HbS 19,20,21,22,23.

HbE results from a single-nucleotide substitution that replaces glutamic acid with lysine at codon 26 of the β-globin gene 19. A majority of affected children in Malaysia harbour this variant 24,25,26. In one cohort, 2 of 29 paediatric patients with HbE/β-thalassemia developed thromboembolic events 27, which may be attributable to genetic predisposition, haemostatic abnormalities, or hepatic dysfunction 28.

HbC arises from the substitution of glutamic acid by lysine at codon 6 of the β-globin chain 20. It is highly prevalent in West Africa, particularly in Ghana 20. Most heterozygous carriers remain asymptomatic; however, homozygotes may present with mild anaemia, jaundice, or splenomegaly 21.

HbS, the hallmark of sickle cell disease, is produced by the replacement of glutamic acid with valine at codon 6 of the β-globin chain 22. This amino-acid change reduces the molecule’s anionic charge and solubility under de-oxygenated conditions, promoting HbS polymerisation, erythrocyte sickling, chronic haemolysis, and recurrent vaso-occlusive crises 23. In 2010 an estimated 305 000 infants were born with sickle cell disease worldwide, and the majority of related childhood deaths occurred in low- and middle-income countries 31.

In Sudan, HbAS and HbSS were reported in 11.3 % and 3.5 %, respectively, of children aged 0–18 years 32. HbSS prevalence is particularly high in Africa, contributing substantially to childhood morbidity and mortality. Carrier frequencies (HbAS) often exceed 20 %, whereas the prevalence of affected individuals (HbSS) is at least 2 % 35. Among 102 Nigerian children aged 7 months–17 years, 97.1 % had HbSS, whereas 2.9 % had HbSC. In Cameroon, screening of 703 infants revealed HbSS in 0.7 %, HbS/β+-thalassemia in 0.6 %, and HbAS in 16.8 % 36. Comparable figures have been documented in the Congo, where 1.4 % of 204 neonates carried HbSS and 16.9 % carried HbAS 37,38. These data from Sudan, Nigeria, Cameroon, and the Congo underline the urgency of implementing universal newborn screening and early-intervention programmes to mitigate sickle cell-related morbidity and mortality.

Membranopathy

Hereditary spherocytosis (HS) is an inherited membranopathy caused by defects in red blood cell membrane proteins, which can lead to hemolytic anemia. HS is characterized by abnormally spherical red blood cells (spherocytes) that are more fragile than normal disc-shaped erythrocytes and therefore have a shortened lifespan. In children, HS can be detected by the presence of spherocytes on a peripheral blood smear 39. There is an association between HS and anemia, leading to several clinical manifestations such as jaundice, risk of gallstones, splenomegaly, functional hyposplenia, and reticulocytosis 40. The severity of anemia in HS varies, ranging from mild to severe 41.

The bar chart in Figure 1 summarizes the clinical features of HS reported in five pediatric studies comprising 137 patients published between 1991 and 2021 42,43,44,45,46. Most pediatric cases present with anemia, followed by splenomegaly, transfusion requirement, jaundice, and neonatal jaundice. HS is more frequent in Northern Europeans than in Southeast Asians. The number of pediatric patients with gallstones was relatively low. Nevertheless, the current incidence and prevalence of HS in Malaysia remain unknown because of the limited number of publications 41,42,43,44,45,46.

Figure 1

Clinical features of hereditary spherocytosis in 137 patients. The bar chart summarizes the frequency of common clinical manifestations reported across five pediatric studies. Abbreviation: HS = Hereditary spherocytosis.

Enzymopathy

Moreover, glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy worldwide, particularly in children. The G6PD gene is located on the X chromosome, specifically in the subtelomeric region (Xq28) 47. The enzyme maintains cellular homeostasis by generating reduced nicotinamide adenine dinucleotide phosphate (NADPH), thereby protecting erythrocytes from oxidative damage and premature destruction; it also functions as a housekeeping enzyme by limiting injury caused by reactive oxygen species (ROS). Because the G6PD gene is X-linked, males are more frequently affected than females: a hemizygous male requires only one defective allele to manifest G6PD deficiency, whereas females possess two copies of the gene and may be homozygous normal, heterozygous (intermediate), or homozygous deficient 48,49. Individuals with G6PD deficiency may develop acute hemolytic anemia following exposure to oxidative foods, medications, or chemical agents—such as fava beans, antimalarial drugs, and aspirin 50,51,52.

The global prevalence of G6PD deficiency is approximately 4.9 % 53. A study by Ainoon et al. 54 described a boy with a history of recurrent fever, pallor, and dark-colored urine after exposure to mosquito repellent and traditional Chinese herbs; laboratory evaluation confirmed hemolytic anemia, and molecular analysis identified a 24-bp deletion of nucleotides 953–976 in exon 9 of the G6PD gene 53,54. A prevalence of 14.4 % was reported among 118 children aged 2–5 years 48. The predominance in males is consistent with the requirement for biallelic mutations in females to express the phenotype 55,56. Consequently, neonatal screening in high-prevalence regions, parental education on the avoidance of oxidative triggers, and genetic counseling are recommended to prevent hemolytic crises and support at-risk families.

Acquired anemia

Acquired anemia may arise from iron deficiency, dietary insufficiency, inflammation, menorrhagia, chronic disorders, and infectious diseases 57,58. Most conditions associated with anemia can be classified into three major groups: anemia of chronic disease, infectious anemia, and nutritional deficiency anemia 59.

Anemia of chronic disease (ACD), also referred to as anemia of chronic inflammation, is one of the most common causes of acquired anemia 60,61,62. Its pathogenesis is mediated by cytokines—including interferon (IFN), interleukins (IL), tumor necrosis factor (TNF), and hepcidin—released after activation of T lymphocytes and macrophages in malignancy and autoimmune disorders. These mediators down-regulate erythropoietin receptors through sustained release of pro-inflammatory cytokines and the generation of reactive oxygen species 63. Consequently, interferon-γ (IFN-γ) exerts direct toxicity on erythroid progenitors, thereby worsening the severity of ACD 64. A concomitant reduction in circulating erythropoietin further aggravates the anemia 65. Inflammatory signaling depletes functional iron stores, leading to a fall in hemoglobin concentration 66. Disruption of iron homeostasis and a shortened red-cell lifespan further contribute to the pathophysiology of ACD 67. Accordingly, the peripheral blood film is typically normocytic–normochromic, although microcytosis can emerge in advanced disease 62,68.

Chronic kidney disease (CKD) is a major cause of ACD because renal impairment limits erythropoietin synthesis. CKD is defined as structural or functional kidney damage with a glomerular filtration rate (GFR) below 60 mL/min/1.73 m² 69. If left untreated, CKD markedly increases the risk of adverse events, including stroke 70. CKD is stratified into five stages of renal dysfunction, which are often asymptomatic in the early phases. Previous studies report a high prevalence of severe normocytic anemia in older adults with stage 5 CKD 71. The prevalence of CKD in children has risen steadily since the 1980s, paralleling an increase in anemia 72. In paediatric patients, CKD-related anemia adversely affects growth and quality of life 72,81. Anemic CKD further heightens the risk of cardiovascular complications 73. CKD-associated anemia is characterized by reduced hemoglobin concentration and a shortened erythrocyte lifespan 82. In the Korean KNOW-PedCKD cohort, Lee et al. (2019) demonstrated that school-aged children with stage 4 CKD had a 31.4 % prevalence of anemia, significantly higher than in earlier stages. Similarly, >20 % of paediatric patients reach end-stage renal disease (ESRD) with concomitant anemia 74,75. Salman et al. (2016) found an anemia prevalence of 83.3 % among female CKD patients in north-eastern Peninsular Malaysia; 79 % had severe and 34.4 % had moderate anemia. Declines in Hb, MCH, and MCHC correlated with worsening renal function in these patients 76. The primary mechanism is inadequate erythropoietin (EPO) production by the diseased kidney, which impairs erythropoiesis 77. Ageing further diminishes EPO responsiveness, exacerbating anemia 78.

Infectious diseases contribute to anemia by disrupting iron metabolism and altering systemic iron balance. In children, the most common infectious contributors are parasitic infections—particularly soil-transmitted helminths (STH) and malaria 79. STH ova mature in soil, facilitating transmission of intestinal worms that disproportionately affect school-aged children. Risk factors include barefoot outdoor play, inadequate hand hygiene, and poor nail care, which enable larval penetration. Prevalence studies of STH-related anemia—principally involving hookworm (Necator americanus, Ancylostoma duodenale), Ascaris lumbricoides, and Trichuris trichiura—are summarized in Table 280,81,82,83,84. STH infection causes gastrointestinal blood loss and impairs nutrient absorption, culminating in iron-deficiency anemia 82. Hookworms secrete anticoagulant molecules that perpetuate occult gastrointestinal bleeding and chronic IDA 83. Low socioeconomic status and specific geographic settings are independently associated with STH burden, underscoring the need for integrated control strategies 80,81,82,83,84.

Table 2

Prevalence of soil transmitted helminth (STH) associated with anemia among children based on many study

NoReferencesCountryStudy populationSample sizeType of studyLaboratory TechniquePrevalence (%)
AnemiaSTHHookwormRoundwormWhipworm
180MalaysiaSchool children254cross sectionalKato-Katz4193.73.947.684.6
281MalaysiaSchool children148cross sectionalFormalin ether concentration37.837.208.7044.9046.40
382IndonesiaSchool children82cross sectionalKato-Katz2.407.30non detected3.702.40
483IndonesiaPreschool children393cross sectionalKato-Katz60.3058.809.247.4036.80
584ThailandSchool children375cross sectionalFormalin ether concentration6.4047.700.5013.3016.30

Malaria is another major infection underlying pediatric anemia. Disease severity correlates with transmission intensity, vector density, longevity, biting behaviour, and vector competence. Plasmodium falciparum and P. vivax predominate and are highly prevalent in Asia and sub-Saharan Africa 85. Between 2000 and 2019, 279 paediatric cases of malaria-associated anemia were reported (Table 3). The majority involved P. falciparum, which is notorious for severe disease and marked haemolysis 85,86,87,88.

Table 3

Summary for malaria cases that is associated with anemia condition

NoCountryYears of studyNo sampleAge (years old)SpeciesAnemic (Hb level in g/dL)SevereModerateMildReferences
1Malaysia2009220<15P.knowlesi & P. Falciparum30 (<10)NSNSNS85
2Vietnam2012-201947<15P. falciparum47 (<11)344086
3Laos2010-20113192.5-10P. falciparum92 (11.5)2494187
4Thailand-Myanmar Border2000-2016926<15P. falciparum & P. vivax110 (<5)110NSNS88

Nutrient deficiencies are a common cause of anemia, particularly in children of both sexes. Dietary imbalances increase the risk of the most prevalent micronutrient deficiencies, namely vitamin B12, folic acid and, in particular, iron deficiency 89. Prolonged depletion of vitamin B12, folic acid or iron stores leads to megaloblastic anemia, iron-deficiency anemia, or to the simultaneous occurrence of both 90.

Adequate iron intake is essential for fetal and infant development 91,92. Iron deficiency is the most widespread nutritional inadequacy associated with anemia; it affects more than 30 % of the global population and is the leading contributor to the condition 1,93,94. Malnutrition significantly lowers haemoglobin, mean corpuscular haemoglobin (MCH) and mean corpuscular volume (MCV) in children under five years of age. The prevalence of iron-deficiency anemia (IDA) and iron deficiency (ID) is about 40 % among pre-school children in low- and middle-income countries 95. Among five-year-old children, the prevalence of IDA is 18.6 % (55/295). In Malaysia, approximately 4 % of primary-school children are anemic 96,97. Long-term IDA adversely affects neurodevelopment, including neurotransmitter metabolism and memory function 98.

These findings underscore the substantial burden of anemia in paediatric populations, particularly in endemic regions where repeated infections such as malaria and co-existing nutritional deficiencies further aggravate anemia severity.

Conclusion

Addressing pediatric anemia requires an integrated approach that combines clinical interventions, public-health initiatives, and ongoing research. For inherited disorders such as HbE/β-thalassemia, expansion of newborn screening, provision of genetic counseling, and investigation of genetic modifiers are critical for early detection and optimum management. In cases of acquired anemia, priority should be given to strengthening nutrition programmes, implementing infection-control measures, and increasing public awareness. Enhanced global collaboration among researchers, policy-makers, and public-health agencies is essential to develop sustainable solutions and to mitigate the worldwide burden of childhood anemia. Nevertheless, substantial knowledge gaps persist, particularly regarding the contribution of genetic modifiers to inherited anemias and the optimisation of targeted therapies. Additional investigations into epigenetic determinants of disease severity, innovative pharmacotherapies, and affordable gene-based treatments are required to transform the management of anemia.

Abbreviations

ACD: Anemia of Chronic Disease; CKD: Chronic Kidney Disease; EPO: Erythropoietin; ESRD: End-Stage Renal Disease; FRGS: Fundamental Research Grant Scheme; GFR: Glomerular Filtration Rate; G6PD: Glucose-6-Phosphate Dehydrogenase; Hb: Hemoglobin; HS: Hereditary Spherocytosis; IDA: Iron-Deficiency Anemia; IFN: Interferon; IFN-γ: Interferon-gamma; IL: Interleukins; MCH: Mean Corpuscular Hemoglobin; MCHC: Mean Corpuscular Hemoglobin Concentration; MCV: Mean Corpuscular Volume; NADPH: Nicotinamide Adenine Dinucleotide Phosphate; RBCs: Red Blood Cells; ROS: Reactive Oxygen Species; STH: Soil-Transmitted Helminths; TNF: Tumor Necrosis Factor; WHO: World Health Organization

Acknowledgments

This study was supported by Fundamental Research Grant Scheme (FRGS); 203.PPSP.6171251.

Author’s contributions

Siti Nur Nabeela A'ifah Mohammad and Zefarina Zulkafli contributed to conceptualization; Wan Suriana Wan Ab Rahman and Mohd Nazri Hassan were involved in methodology; Siti Nur Nabeela A'ifah Mohammad and Zefarina Zulkafli contributed to writing original draft preparation; Hisham Atan Edinur, Wan Suriana Wan Ab Rahman and Mohd Nazri Hassanwere involved in writing, review and editing; and all authors have read, approved the final manuscript and agreed to the published.

Funding

None.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Declaration of generative AI and AI-assisted technologies in the writing process

The authors declare that they have not used generative AI (a type of artificial intelligence technology that can produce various types of content including text, imagery, audio and synthetic data. Examples include ChatGPT, NovelAI, Jasper AI, Rytr AI, DALL-E, etc) and AI-assisted technologies in the writing process before submission.

Competing interests

The authors declare that they have no competing interests.

  1. E. McLean, M. Cogswell, I. Egli, D. Wojdyla, B. de Benoist. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr 2009; 12(4): 444-454.
  2. C. R. Zuffo, M. M. Osório, C. A. Taconeli, S. T. Schmidt, B. H. da Silva, C. C. Almeida. Prevalence and risk factors of anemia in children. J Pediatr (Rio J) 2016; 92(4): 353-360.
  3. T. Konstantyner, T. Cláudia, R. Oliveira, J. Augusto De Aguiar, C. Taddei. Risk Factors for Anemia among Brazilian Infants from the 2006 National Demographic Health Survey. 2012; :
  4. Y. Kim, J. Park, M. Kim. Diagnostic approaches for inherited hemolytic anemia in the genetic era. Blood Research 2017; 52: 84-94.
  5. R. Galanello, R. Origa. Beta-thalassemia. Orphanet J Rare Dis 2010; 5(1): 11.
  6. E. Kohne. Hemoglobinopathies: Clinical Manifestations, Diagnosis, and Treatment. Dtsch Arztebl Int 2011; 108(31-32): 532.
  7. A. Cao, R. Galanello. Beta-thalassemia. Genet Med 2010; 12(2): 61-76.
  8. R. Yousuf, S. Akter, S. M. Wasek, S. Sinha, R. Ahmad, M. Haque. Thalassemia: A Review of the Challenges to the Families and Caregivers. Cureus 2022; :
  9. D. Chandra Sharma, A. Arya, P. Kishor, P. Woike, J. Bindal. Overview on Thalassemias: A review article. Med Res Chronicles 2017; 4(3): 325-337.
  10. K. Zhong, H. Shi, W. Wu, H. Xu, H. Wang, Z. Zhao. Genotypic spectrum of α-thalassemia and β-thalassemia in newborns of the Li minority in Hainan province, China. Front Pediatr 2023; 11:
  11. L. C. Chan, S. K. Ma, A. Y. Chan, S. Y. Ha, J. S. Waye, Y. L. Lau. Should we screen for globin gene mutations in blood samples with mean corpuscular volume (MCV) greater than 80 fL in areas with a high prevalence of thalassaemia?. J Clin Pathol 2001; 54(4): 317-320.
  12. D. Vijian, W. S. Wan Ab Rahman, K. T. Ponnuraj, Z. Zulkafli, R. Bahar, N. Yasin. Gene Mutation Spectrum among Alpha-Thalassaemia Patients in Northeast Peninsular Malaysia. Diagnostics (Basel) 2023; 13(5): 894.
  13. H. Srivorakun, G. Fucharoen, Y. Changtrakul, P. Komwilaisak, S. Fucharoen. Thalassemia and hemoglobinopathies in Southeast Asian newborns: diagnostic assessment using capillary electrophoresis system. Clin Biochem 2011; 44(5-6): 406-411.
  14. R. Bahar, S. M. Sahid, M. Ramli, N. H. Noor, S. M. Yusoff, S. M. Arifin. Molecular and haematological characterization of deletional alpha thalassemia in northeastern Malaysia. Bangladesh J Med Sci 2023; 22(2): 410-415.
  15. E. George, A. Rahman Jamal, F. Khalid, K. Ariffin Osman, K. Malaysia, J. Yaacob Latif. High Performance Liquid Chromatography (HPLC) as a Screening Tool for Classical Beta-Thalassaemia Trait in Malaysia. Malays J Med Sci 2001; 8(2): 40.
  16. A. Ismail, M. J. Campbell, H. M. Ibrahim, G. L. Jones. Health related quality of life in Malaysian children with thalassaemia. Health Qual Life Outcomes 2006; 4: 39.
  17. A. Kattamis, G. L. Forni, Y. Aydinok, V. Viprakasit. Changing patterns in the epidemiology of β‐thalassemia. Eur J Haematol 2020; 105(6): 692.
  18. C. S. Thom, C. F. Dickson, D. A. Gell, M. J. Weiss. Hemoglobin Variants: Biochemical Properties and Clinical Correlates. Cold Spring Harb Perspect Med 2013; 3(3):
  19. S. Fucharoen, D. J. Weatherall. The Hemoglobin E Thalassemias. Cold Spring Harb Perspect Med 2012; 2(8):
  20. F. B. Piel, R. E. Howes, A. P. Patil, O. A. Nyangiri, P. W. Gething, S. Bhatt. The distribution of haemoglobin C and its prevalence in newborns in Africa. Sci Rep 2013; 3: 1671.
  21. B. Karna, S. K. Jha, E. Al Zaabi. Hemoglobin C Disease. 2020; :
    https://www.ncbi.nlm.nih.gov/books/NBK559043/Google Scholar
  22. P. Sebastiani, J. J. Farrell, A. Alsultan, S. Wang, H. L. Edward, H. Shappell. BCL11A enhancer haplotypes and fetal hemoglobin in sickle cell anemia. Blood Cells Mol Dis 2015; 54(3): 224-230.
  23. G. J. Kato, F. B. Piel, C. D. Reid, M. H. Gaston, K. Ohene-Frempong, L. Krishnamurti. Sickle cell disease. Nat Rev Dis Primers 2018; 4(1): 18010.
  24. H. Mohd Ibrahim, Z. Muda, I. S. Othman, M. N. Mohamed Unni, K. H. Teh, A. Thevarajah. Observational study on the current status of thalassaemia in Malaysia: a report from the Malaysian Thalassaemia Registry. BMJ Open 2020; 10(6): e037974.
  25. S. B. Hanafi, W. Z. Abdullah, R. A. Adnan, R. Bahar, M. F. Johan, N. F. Azman. Genotype-Phenotype Association of Hbe/β-Thalassemia Disease and the Role of Genetic Modifiers. Malaysian J Paediatr Child Heal 2016; 22: 1-16.
  26. N. F. Olivieri, Z. Pakbaz, E. Vichinsky. Hb E/beta-thalassemia: A common & clinically diverse disorder. Indian J Med Res 2011; 134: 522-531.
  27. N. Sirachainan, A. Chuansumrit, P. Kadegasem, W. Sasanakul, P. Wongwerawattanakoon, L. Mahaklan. Normal hemostatic parameters in children and young adults with α-thalassemia diseases. Thromb Res 2016; 146: 35-42.
  28. V. Sharma, B. Kumar, R. Ahuja, R. Saxena. High Frequency of Thrombogenic Markers in Polytransfused HbE-Thalassemia. Blood 2007; 110(11): 3983.
  29. E. Wastnedge, D. Waters, S. Patel, K. Morrison, M. Y. Goh, D. Adeloye. The global burden of sickle cell disease in children under five years of age: A systematic review and meta-analysis. J Glob Health 2018; 8(2):
  30. M. A. Adam, N. K. Adam, B. A. Mohamed. Prevalence of sickle cell disease and sickle cell trait among children admitted to Al Fashir Teaching Hospital North Darfur State, Sudan. BMC Res Notes 2019; 12(1): 659.
  31. S. D. Grosse, I. Odame, H. K. Atrash, D. D. Amendah, F. B. Piel, T. N. Williams. Sickle cell disease in Africa: A neglected cause of early childhood mortality. Am J Prev Med 2011; 41: S398-S405.
  32. N. S. Françoise, D. M. Njangtang, B. C. Chemegni, V. P. Djientcheu. Prevalence of sickle cell disease in newborns in the Yaounde Central Hospital. J Med Res 2017; 3(6): 277-279.
  33. L. Tshilolo, L. M. Aissi, D. Lukusa, C. Kinsiama, S. Wembonyama, B. Gulbis. Neonatal screening for sickle cell anaemia in the Democratic Republic of the Congo: experience from a pioneer project on 31 204 newborns. J Clin Pathol 2009; 62(1): 35-38.
  34. E. R. Meier, J. L. Miller. Sickle cell disease in children. Drugs 2012; 72(7): 895-906.
  35. S. C. Steward, A. R. Chauvenet, C. O’Suoji. Hereditary spherocytosis: Consequences of delayed diagnosis. SAGE Open Med 2014; :
  36. M. Pizzi, F. Fuligni, L. Santoro, E. Sabattini, M. Ichino, R. De Vito. Spleen histology in children with sickle cell disease and hereditary spherocytosis: hints on the disease pathophysiology. Hum Pathol 2017; 60: 95-103.
  37. O. Ciepiela. Old and new insights into the diagnosis of hereditary spherocytosis. Ann Transl Med 2018; 6(17): 339-339.
  38. M. M. Sultana, M. S. Islam, M. S. Mia. Hereditary Spherocytosis in a 22 Month Old Child. TAJ J Teach Assoc 2018; 30(2): 79-82.
  39. A. Das, D. Bansal, R. Das, A. Trehan, R. K. Marwaha. Hereditary spherocytosis in children: profile and post-splenectomy outcome. Indian Pediatr 2014; 51(2): 139-141.
  40. M. T. Koh, S. C. Ng. Hereditary spherocytosis: a study of 16 patients from University Hospital, Kuala Lumpur. Singapore Med J 1991; 32(1): 67-69.
  41. Y. Wu, L. Liao, F. Lin. The diagnostic protocol for hereditary spherocytosis-2021 update. J Clin Lab Anal 2021; 35(12): e24034.
  42. F. Xie, L. Lei, B. Cai, L. Gan, Y. Gao, X. Liu. Clinical manifestation and phenotypic analysis of novel gene mutation in 28 Chinese children with hereditary spherocytosis. Mol Genet Genomic Med 2021; 9(4): e1577.
  43. N. S. Reading, M. M. Sirdah, M. E. Shubair, B. E. Nelson, M. S. Al-Kahlout, J. M. Al-Tayeb. Favism, the commonest form of severe hemolytic anemia in Palestinian children, varies in severity with three different variants of G6PD deficiency within the same community. Blood Cells Mol Dis 2016; 60: 58-64.
  44. I. Z. Isaac, A. S. Mainasara, O. Erhabor, S. T. Omojuyigbe, M. K. Dallatu, L. S. Bilbis. Glucose-6-phosphate dehydrogenase deficiency among children attending the Emergency Paediatric Unit of Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria. 2013; : 557-562.
  45. T. T. Shenkutie, D. Nega, A. Hailu, D. Kepple, L. Witherspoon, E. Lo. Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern Ethiopia. Malar J 2022; 21(1): 260.
  46. C. Baldwin, O. Olarewaju. Hemolytic Anemia. StatPearls 2020; :
  47. D. Hernández-Pérez, C. Butrón-Téllez Girón, S. Ruiz-Rodríguez, A. Garrocho-Rangel, A. Pozos-Guillén. Dental considerations in children with glucose-6-phosphate dehydrogenase deficiency (favism): A review of the literature and case report. Case Rep Dent 2015; 2015: 506459.
  48. S. Ladogana, M. Maruzzi, P. Samperi, S. Perrotta, G. C. Del Vecchio, L. D. Notarangelo. Diagnosis and management of newly diagnosed childhood autoimmune haemolytic anaemia. Recommendations from the Red Cell Study Group of the Paediatric Haemato-Oncology Italian Association. Blood Transfus 2017; 15(3): 259-267.
  49. H. Mansor, E. R. Tohit, F. Idris, A. A. Rahman. Prevalence, sociodemographic and clinical characteristics of G6PD deficient blood donors in Terengganu and the effects of storage on their donated blood. Malaysian J Med Heal Sci 2020; 16(2): 126-134.
  50. O. Ainoon, N. Y. Boo, Y. H. Yu, S. K. Cheong, H. N. Hamidah. G6PD deficiency with hemolytic anemia due to a rare gene deletion—a report of the first case in Malaysia. Hematology 2006; 11(2): 113-118.
  51. H. Y. Lee, A. Ithnin, R. Z. Azma, A. Othman, A. Salvador, F. C. Cheah. Glucose-6-Phosphate Dehydrogenase Deficiency and Neonatal Hyperbilirubinemia: Insights on Pathophysiology, Diagnosis, and Gene Variants in Disease Heterogeneity. Front Pediatr 2022; 10: 875877.
  52. N. S. Gampio Gueye, S. M. Peko, D. Nderu, F. Koukouikila-Koussounda, C. Vouvoungui, S. C. Kobawila. An update on glucose-6-phosphate dehydrogenase deficiency in children from Brazzaville, Republic of Congo. Malar J 2019; 18(1): 57.
  53. Y. Balarajan, U. Ramakrishnan, E. Özaltin, A. H. Shankar, S. V. Subramanian. Anaemia in low-income and middle-income countries. Lancet 2011; 378(9809): 2123-2135.
  54. V. G. Sankaran, M. J. Weiss. Anemia: Progress in molecular mechanisms and therapies. Nat Med 2015; 21(3): 221-230.
  55. J. A. Moreno Chulilla, M. S. Romero Colás, M. Gutiérrez Martín. Classification of anemia for gastroenterologists. World J Gastroenterol 2009; 15(37): 4627-4637.
  56. E. Poggiali, M. Migone De Amicis, I. Motta. Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases. Eur J Intern Med 2014; 25(1): 12-17.
  57. G. Weiss. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002; 16(2): 87-96.
  58. T. Ganz. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer 2006; 46(5): 554-557.
  59. F. Morceau, M. Dicato, M. Diederich. Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. Mediators Inflamm 2009; 2009: 405016.
  60. C. Q. Wang, K. B. Udupa, D. A. Lipschitz. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J Cell Physiol 1995; 162(1): 134-138.
  61. J. O. Cullis. Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol 2011; 154(3): 289-300.
  62. A. J. Madu, M. D. Ughasoro. Anaemia of Chronic Disease: An In-Depth Review. Med Princ Pract 2017; 26(1): 1-9.
  63. B. J. Cherayil. Pathophysiology of iron homeostasis during inflammatory states. J Pediatr 2015; 167: 15-19.
  64. J. Cullis. Anaemia of chronic disease. Clin Med J R Coll Physicians London 2013; 13(2): 193-196.
    View Articlehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4952640/Google Scholar
  65. H. Shaikh, N. R. Aeddula. Anemia Of Chronic Renal Disease 2020; :
    https://www.ncbi.nlm.nih.gov/books/NBK539871/Google Scholar
  66. J. L. Abramson, C. T. Jurkovitz, V. Vaccarino, W. S. Weintraub, W. McClellan. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 2003; 64(2): 610-615.
  67. M. Salman, A. H. Khan, A. S. Adnan, S. A. Sulaiman, K. Hussain, N. Shehzadi. Prevalence and management of anemia in pre-dialysis Malaysian patients: A hospital-based study. Rev Assoc Med Bras 2016; 62(8): 742-747.
  68. F. Becherucci, R. M. Roperto, M. Materassi, P. Romagnani. Chronic kidney disease in children. Nephrology 2016; 9(4): 583-591.
  69. K. H. Lee, E. Park, H. J. Choi, H. G. Kang, I. S. Ha, H. I. Cheong. Anemia and Iron Deficiency in Children with Chronic Kidney Disease (CKD): Data from the Know-Ped CKD Study. J Clin Med 2019; 8(2): 152.
  70. G. Ardissino, V. Daccò, S. Testa, R. Bonaudo, A. Claris-Appiani, E. Taioli. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 2003; 111(4 Pt 1): e382-e387.
  71. K. Der Medizinischen, H. Hannover. Pediatric Nephrology Occasional survey Association : 20 years ’ experience. Pediatr Nephrol 1993; : 758-768.
  72. B. Poudel, B. K. Yadav, B. Jha, K. B. Raut, D. R. Pandeya. Prevalence and association of anemia with CKD: A hospital based cross-sectional study from Nepal. Biomed Res 2013; 24(1): 99-103.
  73. T. Akizawa, H. Okumura, A. F. Alexandre, A. Fukushima, G. Kiyabu, J. Dorey. Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review. Ther Apher Dial 2018; 22(5): 444-456.
  74. T. Kuragano, K. Mizusaki, T. Kimura, T. Nakanishi. Contributions to Nephrology 2019; : 135-143.
  75. J. R. Matangila, J. Y. Doua, S. Linsuke, J. Madinga, R. Inocêncio Da Luz, J. P. Van Geertruyden. Malaria, schistosomiasis and soil transmitted helminth burden and their correlation with anemia in children attending primary schools in kinshasa, democratic republic of congo. PLoS One 2014; :
    /pmc/articles/PMC4220949/Google Scholar
  76. A. Ahmed, H. M. Al-Mekhlafi, A. H. Al-Adhroey, I. Ithoi, A. M. Abdulsalam, J. Surin. The nutritional impacts of soil-transmitted helminths infections among Orang Asli schoolchildren in rural Malaysia. Parasit Vectors 2012; 5(1): 119.
  77. F. I. Alaribi, N. Z. Unyah, Norashiqin Misni, S. N. Masri, Malina Osman. The prevalence of soil-transmitted helminths infection and its association with anaemia among refugee school children in the Klang Valley, Malaysia. Malaysian Journal of Medicine and Health Sciences 2020; 16: 46-53.
  78. M. Sari, T. Nathasaria, E. Majawati, H. Pangaribuan. Soil-Transmitted Helminth Infections, Anemia, and Undernutrition Among School-Children in An Elementary School in North Jakarta, Indonesia. Maj Kedokt Bdg 2020; 52(4): 205-212.
  79. Y. Djuardi, G. Lazarus, D. Stefanie, U. Fahmida, I. Ariawan, T. Supali. Soil-transmitted helminth infection, anemia, and malnutrition among preschool-age children in Nangapanda subdistrict, Indonesia. PLoS Negl Trop Dis 2021; 15(6): e0009506.
  80. J. Yanola, W. Nachaiwieng, S. Duangmano, M. Prasannarong, S. Pornprasert. Current prevalence of intestinal parasitic infections and their impact on hematological and nutritional status among Karen hill tribe children in Omkoi District, Chiang Mai Province, Thailand. Acta Trop 2018; 180: 1-6.
  81. B. E. Barber, T. William, M. J. Grigg, J. Menon, S. Auburn, J. Marfurt. A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013; 56(3): 383-397.
  82. M. T. Ha, T. A. Ho, A. N. Nguyen, T. A. Nguyen. Characteristics of severe malaria in hospitalized children in Ho Chi Minh City from 2012 to 2019. Trop Biomed 2021; 38(3): 371-376.
  83. T. Akiyama, T. Pongvongsa, S. Phrommala, T. Taniguchi, Y. Inamine, R. Takeuchi. Asymptomatic malaria, growth status, and anaemia among children in Lao People’s Democratic Republic: a cross-sectional study. Malar J 2016; 15(1): 499.
  84. C. S. Chu, M. Stolbrink, D. Stolady, M. Saito, C. Beau, K. Choun. Severe Falciparum and Vivax Malaria on the Thailand-Myanmar Border: A Review of 1503 Cases. Clin Infect Dis 2023; 77(5): 721-728.
  85. M. B. Zimmermann, R. F. Hurrell. Nutritional iron deficiency. Lancet 2007; 370(9586): 511-520.
  86. T. D. Johnson-Wimbley, D. Y. Graham. Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol 2011; 4(3): 177-184.
  87. N. M. Abu-Ouf, M. M. Jan. The impact of maternal iron deficiency and iron deficiency anemia on child’s health. Saudi Medical Journal 2015; 36(2): 146-149.
  88. J. C. King. Physiology of pregnancy and nutrient metabolism. American Journal of Clinical Nutrition 2000; 71(5 Suppl): 1218S-1225S.
  89. A. H. Jafari Nodoshan, A. Hashemi, A. Golzar, F. Karami, R. Akhondzaraini. Hematological Indices in Children with Non-organic Failure to Thrive: a Case-Control Study. Iranian Journal of Pediatric Hematology and Oncology 2016; 6(1): 38-42.
  90. R. L. Bailey, KP Jr West, R. E. Black. The epidemiology of global micronutrient deficiencies. Annals of Nutrition and Metabolism 2015; 66 Suppl 2: 22-33.
  91. E. Mantadakis, E. Chatzimichael, P. Zikidou. Iron Deficiency Anemia in Children Residing in High and Low-Income Countries: Risk Factors, Prevention, Diagnosis and Therapy. Mediterranean Journal of Hematology and Infectious Diseases 2020; 12(1): e2020041.
  92. M. Yusof, S. M. Awaluddin, M. Omar, N. A. Ahmad, F. A. Abdul Aziz, R. Jamaluddin. Prevalence of Anaemia among the Elderly in Malaysia and Its Associated Factors: Does Ethnicity Matter?. Journal of Environmental and Public Health 2018; 2018:
  93. S. Nik Shanita, A. Siti Hanisa, A. R. Noor Afifah, S. T. Lee, K. H. Chong, P. George. Prevalence of anaemia and iron deficiency among primary schoolchildren in Malaysia. International Journal of Environmental Research and Public Health 2018; 15(11): 2332.
  94. R. D. Baker, F. R. Greer, J. J. Bhatia, S. A. Abrams, S. R. Daniels, M. B. Schneider. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics 2010; 126(5): 1040-1050.

Comments